LLY241206C540000
- 290.36
- 0.000.00%
Eli Lilly and Co Newsroom
What's Going On With Eli Lilly Stock On Tuesday?
Eli Lilly and Co (LLY.US) seeks to expand the indications for its weight loss medication and will conduct trials to treat addictive behaviors.
Eli Lilly and Co will test a weight loss drug for treating addiction in 2025.
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Novo Nordisk's Wegovy Sales Drop Is Temporary; Forecasts Still on Track -- Market Talk
Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Eli Lilly and Company (LLY) Is Attracting Investor Attention: Here Is What You Should Know
Market-Moving News for December 10th
Express News | B of A Securities Reinstates Buy on Eli Lilly, Announces $997 Price Target
Eli Lilly Analyst Ratings
As Eli Lilly Shares Gain Over 35% YTD, Drugmaker Announces $15B Share Buyback Program And Boosts Dividend By 15%
Eli Lilly Declares Higher Dividend for Fiscal Q1
Eli Lilly and Co To Go Ex-Dividend On February 14th, 2025 With 1.5 USD Dividend Per Share
Express News | Eli Lilly: Pirtobrutinib Prolonged Time to Next Treatment or Death by a Median of 23.9 Months Compared to 10.9 Months in Control Arm
Eli Lilly Reports Results From Phase 3 BRUIN CLL-321 Trial Evaluating Pirtobrutinib; Study's Primary Endpoint Of Progression-Free Survival Was Met At Primary Analysis
Eli Lilly Shares Are Trading Higher After the Company Announced a Share Repurchase Program and Dividend Increase.
Press Release: Lilly Announces New $15 Billion Share Repurchase Program and Seventh Consecutive 15% Dividend Increase